140 results
Keyword Cefotaxime Ibi Remove keyword
-
List item
National expert: Irene Bidault, National Agency For The Safety Of Medicine And Health Products (updated)
- Declaration of interests - 80.05 KB | PDF
- Curriculum Vitae - 16.41 KB | PDF
PDF icon application/pdf ibidault_CV_en.pdf Declaration of interests … PDF icon application/pdf ibidault_DI_en.pdf … -
List item
Orphan designation: Acetylleucine for: Treatment of GM2 gangliosidosis
Date of first decision: 12/12/2017, Positive, Last updated: 25/04/2019acetylleucine (also known as IBI1000) for the treatment of GM2 … acetylleucine (also known as IBI1000) for the treatment of GM2 … -
List item
Press release: Two new medicines for advanced kidney cancer
CHMP, Last updated: 22/07/2016recommendation is based is a Phase Ib/II trial involving 153 patients … complement data from the phase Ib/II trial. The opinions adopted … recommendation is based is a Phase Ib/II trial involving 153 patients … -
List item
National expert: Wei Zhao, European Medicines Agency (updated)
- Declaration of interests - 79.84 KB | PDF
- Curriculum Vitae - 29.36 KB | PDF
-
List item
National expert: Maria Teresa Herdeiro, European Medicines Agency (updated)
- Declaration of interests - 79.78 KB | PDF
- Curriculum Vitae - 29.22 KB | PDF
Present Principal investigator iBiMED - University of Aveiro (Portugal) Research … Herdeiro Organisation/Company: iBiMED University of Aveiro Country … -
List item
National expert: Raúl J. Andrade, Spanish Agency of Medicines and Medical Devices (updated)
- Declaration of interests - 85.79 KB | PDF
- Curriculum Vitae - 38.07 KB | PDF
-
List item
National expert: Anna Wachnik-Święcicka, The Office for Registration of Medicinal Products, Medical Devices and Biocides (updated)
- Declaration of interests - 80.09 KB | PDF
- Curriculum Vitae - 18.93 KB | PDF
of infants2-12 months old (ibid.). 3. Wachnik A., Nagy K … zsiranyagcserere, patkanyban (ibid.). 8. Biro L., Rodics K … aktiyitasara patkany szerumban (ibid.). 11. Antal M., Wachnik … -
List item
National expert: Ewa Widy Tyszkiewicz, The Office for Registration of Medicinal Products, Medical Devices and Biocides (updated)
- Declaration of interests - 79.79 KB | PDF
- Curriculum Vitae - 26.02 KB | PDF
II. Anticholinergic drugs, ibid, 393-399. E. Widy-Tyszkiewicz … Drugs and autonomic Ganglia, ibid, 401-404. [polish] E. Widy-Tyszkiewicz … neuromuscular transduction, ibid, 406-409 [polish] E. Widy-Tyszkiewicz … -
List item
National expert: Ulrich Nordheim, Federal Institute for Drugs and Medical Devices (updated)
- Declaration of interests - 81.66 KB | PDF
- Curriculum Vitae - 18.34 KB | PDF
Cannabinoid Antagonist Ibipinabant (SLV319) Obesity, Diabetes … -
List item
National expert: Jesus Chesa Jimenez, Spanish Agency of Medicines and Medical Devices (updated)
- Declaration of interests - 79.8 KB | PDF
- Curriculum Vitae - 22.13 KB | PDF
J. Farmacocinética de la cefotaxima en la rata. Ciencia Pharmaceutica … -
List item
National expert: María José Torres, European Medicines Agency (updated)
- Declaration of interests - 84.86 KB | PDF
- Curriculum Vitae - 18.81 KB | PDF
Present Head of Research Group IBIMA - Hospital Regional Universitario … Biomedical Research in Málaga (IBIMA). In the latter, I am coordinator … -
List item
National expert: Inmaculada Corrales, Spanish Agency of Medicines and Medical Devices (updated)
- Declaration of interests - 79.78 KB | PDF
- Curriculum Vitae - 23.13 KB | PDF
-
List item
Human medicine European public assessment report (EPAR): Wakix
pitolisant, Narcolepsy
Date of authorisation: 31/03/2016,
, 
, Revision: 10, Authorised, Last updated: 11/03/2021
-
List item
National expert: Ron Mathot, Medicines Evaluation Board (updated)
- Declaration of interests - 80.94 KB | PDF
- Curriculum Vitae - 55.1 KB | PDF
-
List item
Human medicine European public assessment report (EPAR): Lenalidomide Mylan (updated)
lenalidomide, Multiple Myeloma
Date of authorisation: 18/12/2020,
, Revision: 1, Authorised, Last updated: 31/03/2021
-
List item
National expert: María Isabel Lucena, Spanish Agency of Medicines and Medical Devices (updated)
- Declaration of interests - 79.79 KB | PDF
- Curriculum Vitae - 32.75 KB | PDF
-
List item
Human medicine European public assessment report (EPAR): Ledaga
Chlormethine, Mycosis Fungoides
Date of authorisation: 03/03/2017,, Revision: 6, Authorised, Last updated: 10/03/2021
-
List item
Human medicine European public assessment report (EPAR): Vaxzevria (previously COVID-19 Vaccine AstraZeneca) (updated)
ChAdOx1-SARS-COV-2, COVID-19 virus infection
Date of authorisation: 29/01/2021,, 
, Revision: 3, Authorised, Last updated: 13/04/2021
-
List item
Human medicine European public assessment report (EPAR): Kisqali
ribociclib succinate, Breast Neoplasms
Date of authorisation: 22/08/2017,, Revision: 7, Authorised, Last updated: 04/11/2020
-
List item
Human medicine European public assessment report (EPAR): Kisplyx (updated)
lenvatinib mesilate, Carcinoma, Renal Cell
Date of authorisation: 25/08/2016,, 
, Revision: 13, Authorised, Last updated: 07/04/2021
-
List item
Human medicine European public assessment report (EPAR): Imbruvica
Ibrutinib, Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 21/10/2014,, Revision: 21, Authorised, Last updated: 26/02/2021
-
List item
Human medicine European public assessment report (EPAR): Aubagio
Teriflunomide, Multiple Sclerosis
Date of authorisation: 26/08/2013, Revision: 17, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Keppra (updated)
levetiracetam, Epilepsy
Date of authorisation: 29/09/2000, Revision: 49, Authorised, Last updated: 18/03/2021 -
List item
Human medicine European public assessment report (EPAR): Doptelet (updated)
avatrombopag maleate, Thrombocytopenia
Date of authorisation: 20/06/2019,, Revision: 4, Authorised, Last updated: 07/04/2021
-
List item
Human medicine European public assessment report (EPAR): Tecentriq
atezolizumab, Carcinoma, Transitional Cell, Carcinoma, Non-Small-Cell Lung, Urologic Neoplasms, Breast Neoplasms, Small Cell Lung Carcinoma
Date of authorisation: 20/09/2017,, Revision: 13, Authorised, Last updated: 05/03/2021